121 related articles for article (PubMed ID: 38665031)
1. Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway.
Zhang Y; Liu H; Liu X; Lang L
Discov Med; 2024 Apr; 36(183):836-841. PubMed ID: 38665031
[TBL] [Abstract][Full Text] [Related]
2. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
3. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Liao WL; Lin H; Li YH; Yang TY; Chen MC
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
[TBL] [Abstract][Full Text] [Related]
4. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
5. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
8. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
[TBL] [Abstract][Full Text] [Related]
11. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
12. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
13. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression.
Wu J; Tang Q; Ren X; Zheng F; He C; Chai X; Li L; Hann SS
J Ethnopharmacol; 2019 Jun; 237():128-140. PubMed ID: 30910577
[TBL] [Abstract][Full Text] [Related]
15. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
16. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
17. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
19. EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
Lin C; Qin Y; Zhang H; Gao MY; Wang YF
Oncol Rep; 2018 Jul; 40(1):29-38. PubMed ID: 29749533
[TBL] [Abstract][Full Text] [Related]
20. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
